# Lessons learned for spine SABR?

## TL;DR

Spine SABR improves local control and pain response in metastatic tumors, but more research is needed to expand its use globally.

## Contribution

Highlights the clinical benefits and technical feasibility of spine SABR in metastatic disease management.

## Key findings

- Spine SABR achieves high local control rates (75–95%) in metastatic spine tumors.
- Pain response rates vary between 40–90% with SABR treatments.
- Advanced imaging and immobilization systems are increasingly available for SABR.

## Abstract

•SABR has shown survival benefits in oligometastatic cases, particularly in low-volume metastatic disease states.•Spine SABR offers potential improvements in local control, and pain response for metastatic spine tumors.•Technical requirements for SABR, like advanced image guidance and immobilization systems, are increasingly available.•Current data suggests high local control rates (75–95%) and variable pain responses (40–90%) with SABR using single or multi-fraction regimens.•Further randomized trials are needed to explore SABR applications in different scenarios and populations, while considering global health aspects for wider accessibility.

SABR has shown survival benefits in oligometastatic cases, particularly in low-volume metastatic disease states.

Spine SABR offers potential improvements in local control, and pain response for metastatic spine tumors.

Technical requirements for SABR, like advanced image guidance and immobilization systems, are increasingly available.

Current data suggests high local control rates (75–95%) and variable pain responses (40–90%) with SABR using single or multi-fraction regimens.

Further randomized trials are needed to explore SABR applications in different scenarios and populations, while considering global health aspects for wider accessibility.